Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers [NA]
University of Rochester is conducting a clinical trial evaluating a decisional intervention for older adults with acute myeloid leukemia and…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in adul…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating a multi-agent regimen of fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin …
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Ruxolitinib + Allogeneic Stem Cell Transplantation in AML [Phase 2]
A Phase 2 trial assesses combining ruxolitinib with allogeneic stem cell transplantation for acute myeloid leukemia, including AML in remiss…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant [Phase 1]
Phase 1 clinical trial evaluating CMV-MVA Triplex Vaccine to enhance CMV-specific immunity and prevent CMV viremia in patients undergoing ha…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics [Phase 2]
This Phase 2 clinical trial compares CPX-351 to intensive chemotherapy in adults with de novo intermediate- or adverse-risk acute myeloid le…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) [Phase 1]
CERo Therapeutics is conducting a Phase 1 trial of CER-1236 for acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis; the stu…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
This clinical trial update notes a Phase 1 study of BAL0891 by SillaJen in patients with advanced solid tumors, including triple-negative br…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) [Phase 1]
A Phase 1 clinical trial evaluating gilteritinib in combination with either ivosidenib or enasidenib in patients with acute myeloid leukemia…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 [Phase 3]
Phase 3 trial comparing standard-dose versus intermediate-dose cytarabine induction in acute myeloid leukemia with RUNX1-RUNX1T1 fusion; cur…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation [Phase 3]
This clinical trial update notes the ongoing Phase 3 study of Revumenib in combination with intensive chemotherapy for newly diagnosed acute…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Revumenib in Combination With 7+3 + Midostaurin in AML [Phase 1]
Phase 1 trial evaluating Revumenib in combination with standard 7+3 chemotherapy and midostaurin for adult acute myeloid leukemia; currently…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes [Phase 1]
Phase 1 safety and proof-of-concept study of the experimental drug RPT1G in adults with acute myeloid leukemia and high-risk myelodysplastic…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML [Phase 3]
A Phase 3 trial comparing the VAG regimen with a FLT3 inhibitor to standard chemotherapy in adults with FLT3-mutated acute myeloid leukemia,…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide [Phase 1]
Phase 1 clinical trial update evaluating expanded/activated gamma delta T-cell infusion after hematopoietic stem cell transplantation with p…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
This clinical trial update discusses a study of acquired pyruvate kinase deficiency in clonal myeloid neoplasms. The trial is currently acti…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS [Phase 1]
Phase 1 clinical trial update evaluating the combination of everolimus (RAD001) with midostaurin (PKC412) in relapsed, refractory, or poor-p…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 clinical trial evaluating ruxolitinib in combination with venetoclax with and without azacitidine for relapsed or refractory acute m…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
The update describes a Phase 1 trial investigating CD83 CAR T cells for relapsed or refractory acute myeloid leukemia, and the study is curr…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Phase IB/II of CPX-351 for Relapse Prevention in AML [Phase 1, Phase 2]
Clinical trial update on CPX-351 for relapse prevention in acute myeloid leukemia in remission; the Phase 1/Phase 2 study is currently recru…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML [Phase 3]
A Phase 3 clinical trial compares Venetoclax with Azacitidine and Mitoxantrone hydrochloride liposome versus Idarubicin and Cytarabine in ne…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Phase I Study of HC-7366 for Acute Myeloid Leukemia [Phase 1]
A Phase I clinical trial investigating HC-7366 for Acute Myeloid Leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial [Phase 3]
This entry details a Phase 3 extension study of Venetoclax for patients who completed prior Venetoclax trials. The study is currently active…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia [Phase 1, Phase 2]
This clinical trial update outlines an early-phase (Phase 1/2) study evaluating the combination of aclarubicin with azacitidine and venetocl…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients [Phase 2]
This document describes a Phase 2 multicenter randomized trial comparing the standard 3+7 chemotherapy regimen to Venetoclax plus CACAG in n…